Vical to market Allovectin-7 in Turkey
This article was originally published in Scrip
San Diego-based Vical has signed a letter of intent with Eczacibasi Ilac Pazarlama for the sales and marketing of its immunotherapeutic candidate, Allovectin-7, in Turkey. Vical said it would also continue to explore licensing and distribution opportunities in other countries.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.